CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...

Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

The ROS1 inhibitor market for NSCLC, valued at around $290 million in 2023 across the USA, Europe, and Japan, is set for growth with new-generation therapies targeting resistance mutations.

An in-depth analysis in the United States, covering 2002 to 2023, reveals that biological contamination and allergens are the leading causes of food recalls. The study, recently published in the ...

Israel State Auditor Holds Tax Authority Accountable for $800M Crypto Tax Gap: Report ...